Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera)

Trial Profile

Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Ponesimod (Primary) ; Dimethyl fumarate
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms POINT
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 May 2020 to 31 Oct 2020.
    • 10 Aug 2017 Planned primary completion date changed from 1 May 2020 to 31 Oct 2020.
    • 10 Mar 2017 Planned End Date changed from 1 Mar 2020 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top